These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 15148272)
1. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Aihara K; Azuma H; Takamori N; Kanagawa Y; Akaike M; Fujimura M; Yoshida T; Hashizume S; Kato M; Yamaguchi H; Kato S; Ikeda Y; Arase T; Kondo A; Matsumoto T Circulation; 2004 Jun; 109(22):2761-5. PubMed ID: 15148272 [TBL] [Abstract][Full Text] [Related]
2. Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors. Aihara K; Azuma H; Akaike M; Kurobe H; Takamori N; Ikeda Y; Sumitomo Y; Yoshida S; Yagi S; Iwase T; Ishikawa K; Sata M; Kitagawa T; Matsumoto T J Atheroscler Thromb; 2009 Apr; 16(2):127-34. PubMed ID: 19403987 [TBL] [Abstract][Full Text] [Related]
3. Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. Huang PH; Leu HB; Chen JW; Wu TC; Lu TM; Yu-An Ding P; Lin SJ Int J Cardiol; 2007 Jan; 114(2):152-8. PubMed ID: 16650906 [TBL] [Abstract][Full Text] [Related]
4. Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors. Ise T; Aihara K; Sumitomo-Ueda Y; Yoshida S; Ikeda Y; Yagi S; Iwase T; Yamada H; Akaike M; Sata M; Matsumoto T Hypertens Res; 2011 Feb; 34(2):225-31. PubMed ID: 21107326 [TBL] [Abstract][Full Text] [Related]
5. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. Huang SS; Huang PH; Chen YH; Sung SH; Chiang KH; Chen JW; Lin SJ Coron Artery Dis; 2008 Dec; 19(8):597-602. PubMed ID: 18971786 [TBL] [Abstract][Full Text] [Related]
6. Heparin cofactor II attenuates vascular remodeling in humans and mice. Aihara K Circ J; 2010 Aug; 74(8):1518-23. PubMed ID: 20671370 [TBL] [Abstract][Full Text] [Related]
7. Heparin cofactor II as a novel vascular protective factor against atherosclerosis. Aihara K; Azuma H; Akaike M; Sata M; Matsumoto T J Atheroscler Thromb; 2009 Oct; 16(5):523-31. PubMed ID: 19729870 [TBL] [Abstract][Full Text] [Related]
8. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Takamori N; Azuma H; Kato M; Hashizume S; Aihara K; Akaike M; Tamura K; Matsumoto T Circulation; 2004 Feb; 109(4):481-6. PubMed ID: 14744972 [TBL] [Abstract][Full Text] [Related]
9. Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes. Hara T; Uemoto R; Sekine A; Mitsui Y; Masuda S; Kurahashi K; Yoshida S; Otoda T; Yuasa T; Kuroda A; Ikeda Y; Endo I; Honda S; Yoshimoto K; Kondo A; Tamaki T; Matsumoto T; Matsuhisa M; Abe M; Aihara KI J Diabetes Investig; 2021 Dec; 12(12):2172-2182. PubMed ID: 34043882 [TBL] [Abstract][Full Text] [Related]
10. Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Rau JC; Mitchell JW; Fortenberry YM; Church FC Semin Thromb Hemost; 2011 Jun; 37(4):339-48. PubMed ID: 21805439 [TBL] [Abstract][Full Text] [Related]
13. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation. Tran TH; Duckert F Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434 [TBL] [Abstract][Full Text] [Related]
14. [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role]. Rossi EB; Duboscq CL; Kordich LC Medicina (B Aires); 1999; 59(1):95-104. PubMed ID: 10349131 [TBL] [Abstract][Full Text] [Related]
15. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Schillinger M; Exner M; Sabeti S; Mlekusch W; Amighi J; Handler S; Quehenberger P; Kalifeh N; Wagner O; Minar E Thromb Haemost; 2004 Nov; 92(5):1108-13. PubMed ID: 15543340 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Vicente CP; He L; Pavão MS; Tollefsen DM Blood; 2004 Dec; 104(13):3965-70. PubMed ID: 15315969 [TBL] [Abstract][Full Text] [Related]
17. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromsø study. Johnsen SH; Mathiesen EB; Fosse E; Joakimsen O; Stensland-Bugge E; Njølstad I; Arnesen E Circulation; 2005 Jul; 112(4):498-504. PubMed ID: 16027250 [TBL] [Abstract][Full Text] [Related]
18. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Vicente CP; He L; Tollefsen DM Blood; 2007 Dec; 110(13):4261-7. PubMed ID: 17878401 [TBL] [Abstract][Full Text] [Related]
19. Heparin cofactor II modulates the response to vascular injury. Tollefsen DM Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895 [TBL] [Abstract][Full Text] [Related]
20. An enzyme-linked immunosorbent assay for heparin cofactor II (HCII). Application to the measurement of HCII in clinical materials. Toulon P; Costa JM; Amiral J Clin Chim Acta; 1992 Jan; 205(1-2):65-73. PubMed ID: 1521342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]